Patents for C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof (26,637) |
---|
11/05/2002 | US6475718 Genetically engineered eukaryotic cell; for prevention of viral infections; viricides |
11/05/2002 | US6475480 Use of adenoviral E4 reading frames to improve expression of a gene of interest |
11/05/2002 | CA2234396C Method for production of native human leukocyte (alpha) interferon |
10/31/2002 | WO2002086154A2 Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages |
10/31/2002 | WO2002086101A2 Core-glycosylated hcv envelope proteins |
10/31/2002 | WO2002086100A2 Expression of core-glycosylated hcv envelope proteins in yeast |
10/31/2002 | WO2002086072A2 Antimicrobial polypeptides and their uses |
10/31/2002 | WO2002086070A2 Binding molecules for fc-region polypeptides |
10/31/2002 | WO2002086068A2 Methods for producing recombinant coronavirus |
10/31/2002 | WO2002086059A2 Recombinant vaccinia viral vectors |
10/31/2002 | WO2002085932A2 Constructs and methods for expression of recombinant hcv envelope proteins |
10/31/2002 | WO2002085930A2 Immunomodulating agents from parasitic worms and method for isolation thereof |
10/31/2002 | WO2002085416A1 Viral vectors having reduced virulence |
10/31/2002 | WO2002085411A1 Smallpox vaccine |
10/31/2002 | WO2002070565A9 High-affinity antagonists of elr-cxc chemokines |
10/31/2002 | WO2002061048A3 In vitro system for replication of rna-dependent rna polymerase (rdrp) viruses |
10/31/2002 | WO2002031137A3 Cytomegalovirus intron a fragments |
10/31/2002 | WO2002029075A3 Multiple inducible gene regulation system |
10/31/2002 | WO2002008434A3 Bicistronic influenza comprising two genes in tandem |
10/31/2002 | US20020162123 For therapy of tumors |
10/31/2002 | US20020160971 Retroviral vectors with foreign-sequence insertion between retroviral primer binding site and retroviral splice donor |
10/31/2002 | US20020160501 Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
10/31/2002 | US20020159993 Immortal cell line derived from grouper epinephelus coioides and its applications therein |
10/31/2002 | DE10121283A1 Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen Methods and vectors for amplification or expression of the desired nucleic acid sequences in plants |
10/31/2002 | CA2444945A1 Recombinant vaccinia viral vectors |
10/31/2002 | CA2444819A1 Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages |
10/31/2002 | CA2444747A1 Smallpox vaccine |
10/31/2002 | CA2444743A1 Viral vectors having reduced virulence |
10/31/2002 | CA2444683A1 Antimicrobial polypeptides and their uses |
10/31/2002 | CA2444680A1 Binding molecules for fc-region polypeptides |
10/31/2002 | CA2444006A1 Expression of core-glycosylated hcv envelope proteins in yeast |
10/31/2002 | CA2443781A1 Core-glycosylated hcv envelope proteins |
10/31/2002 | CA2443740A1 Constructs and methods for expression of recombinant hcv envelope proteins |
10/30/2002 | EP1253201A2 Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor |
10/30/2002 | EP1253197A1 Attenuated recombinant rabies virus and live vaccines thereof |
10/30/2002 | EP1252323A2 Virus strains for the oncolytic treatment of cancer |
10/30/2002 | EP1252322A2 Herpes virus strains for gene therapy |
10/30/2002 | EP1252321A1 Replication deficient adenovirus vectors |
10/30/2002 | EP1252309A2 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
10/30/2002 | EP0699076B1 Otitis media vaccine |
10/30/2002 | CA2383819A1 Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease |
10/30/2002 | CA2344208A1 Method |
10/29/2002 | US6472212 Methods and compositions for genetically modifying primate bone marrow cells |
10/29/2002 | US6472140 α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease. |
10/29/2002 | US6471962 Monoclonal antibodies for infectious bursal disease, vaccines and assays for use therewith |
10/29/2002 | CA2221242C Viral agent associated with mystery swine disease |
10/24/2002 | WO2002083925A2 Papaya ringspot virus genes |
10/24/2002 | WO2002083881A1 Methods for detecting and adjusting replication of hepatitis b virus and for preparing mutated virus strains with altered replication efficiency |
10/24/2002 | WO2002083880A1 Mosaic adenoviral vectors |
10/24/2002 | WO2002083736A2 G-protein coupled receptor molecules and uses thereof |
10/24/2002 | WO2002074941A8 Reporter virus comprising heterologous envelope proteins |
10/24/2002 | WO2002054873A3 Microbiological agents for the control of sea lice |
10/24/2002 | WO2001025484A3 Methods to inhibit or enhance the binding of viral dna to genomic host dna |
10/24/2002 | US20020156039 Sal2 has a tumor suppressive effect; Sal2 may also be used as an anti-viral agent that interferes with the ability of a DNA tumor virus to replicate in a cell |
10/24/2002 | US20020156017 Antimicrobial peptides and methods of use thereof |
10/24/2002 | US20020155987 Isolated endostatin, especially approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII |
10/24/2002 | US20020155610 High-efficiency wild-type-free AAV helper functions |
10/24/2002 | US20020155608 Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions |
10/24/2002 | US20020155602 Vectors, cells and methods for the production of deleterious viral eukaryotic gene transfer vectors |
10/24/2002 | US20020155582 Genetically engineered ciral particles for use in the prevention of viral diseases |
10/24/2002 | US20020155580 Recombinant aav vectors for gene therapy of hemophilia a |
10/24/2002 | US20020155577 Compound for use in the treatment of parkinson's disease |
10/24/2002 | US20020155532 Method of producing biologically active human acidic fibroblast growth factor and its use in promotiong angiogenesis |
10/24/2002 | US20020155529 Viral vectors having reduced virulence |
10/24/2002 | US20020155432 Genetically engineered herpes virus for the treatment of cardiovascular disease |
10/24/2002 | US20020155430 Lentiviral vector system for high quantity screening |
10/24/2002 | US20020155428 Retrovirus from the HIV group and its use |
10/24/2002 | US20020155131 Recombinant equine herpesvirus type 1 (EHV-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine |
10/24/2002 | US20020155127 Genetic vaccine against human immunodeficiency virus |
10/24/2002 | US20020155124 For enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans |
10/24/2002 | US20020155122 Immunologically significant herpes simplex virus antigens and methods for identifying and using same |
10/24/2002 | CA2445626A1 Mosaic adenoviral vectors |
10/24/2002 | CA2438107A1 G-protein coupled receptor molecules and uses thereof |
10/23/2002 | EP1250593A1 IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs) |
10/23/2002 | EP1250446A1 Replication competent herpes virus strains |
10/23/2002 | EP1250421A1 Recombinant flaviviruses and methods of use thereof |
10/23/2002 | EP1250292A1 Process and means to prevent microorganisms blooming in an aquatic system |
10/23/2002 | EP1250161A2 Polymer blends as biodegradable matrices for preparing biocomposites |
10/23/2002 | EP1250143A2 Reduction in bacterial colonization by administering bacteriophage compositions |
10/23/2002 | EP1250053A2 Method for produce sanitation using bacteriophages |
10/23/2002 | EP1250050A2 Method and device for sanitation using bacteriophages |
10/23/2002 | CN1376201A Immunologically significant herpes simplex virus antigens |
10/23/2002 | CN1376163A Highly purified cytokine activating factor and methods of use |
10/23/2002 | CN1093172C Hepatitis C virus and its external cell culture method |
10/23/2002 | CA2382993A1 Attenuated recombinant rabies virus mutants and live vaccines thereof |
10/22/2002 | US6468778 Process for the inactivation of viruses |
10/22/2002 | US6468777 Through enhanced control and stabilization of protein production via stress proteins and the resultant protein products |
10/22/2002 | US6468771 Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal DNA of target cells |
10/22/2002 | US6468738 First polypeptide fused to a filamentous phage membrane cpviii anchor domain; mutating immunoglobulin variable domain-coding nucleotide sequence in the provided genome to form library of phage particles; immunoglobulin vh polypeptide (antibody heavy |
10/22/2002 | US6468737 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders |
10/22/2002 | US6468733 Method of the inactivation of viruses by a solvent-detergent combination and nanofiltration |
10/22/2002 | US6468544 Genetically engineered influenza a virus with an interferon-inducing phenotype wherein said virus comprises a viral genome wherein the complete ns1 coding sequences have been deleted (delns1). |
10/22/2002 | CA2216601C Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies |
10/22/2002 | CA2188447C Recombinant poxviruses with foreign polynucleotides in essential regions |
10/17/2002 | WO2002081712A2 Artificial chromosomes comprising ehv sequences |
10/17/2002 | WO2002081655A2 Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo |
10/17/2002 | WO2002081511A1 Neurovirulent strain of the west nile virus and applications thereof |
10/17/2002 | WO2002081494A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
10/17/2002 | WO2002080681A1 Chimeric cell-targeting pathogenic organism and method of therapeutic use |
10/17/2002 | WO2002060924A3 Identification and applications of porcine reproductive and respiratory syndrome virus host susceptibility factor(s) for improved swine breeding and development of a non-simian recombinant cell line for propagation of the virus and a target for a novel class of antiviral compounds |